BioTuesdays

Tag - SNTI

Developments

FDA grants Senti RMAT for SENTI-202 in R/R AML

Senti Bio (NASDAQ: SNTI) has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen...

December 9, 2025
Executive Moves

Bryan Baum joins Senti’s BOD

Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio...

July 18, 2025